The Biostatistics and Computational Biology Core of the Cancer Center was established in 1994 with the goal of assuring appropriate biostatistical support to cancer-related research at UCSF. In 2011, at the suggestion of an external advisory board, the Core was split into two separate cores: 1) Biostatistics Core and 2) Computational Biology Core. This division was undertaken as a reflection of the distinct needs of projects focusing on clinical and laboratory studies involving standard statistical approaches and those involving genomics and requiring high performance computing services. Because some projects may require both types of support, the Cores are closely coordinated. There is no overlap of services provided by each core, and funding is not duplicated for the same services in two cores. The major functions of the Biostatistics Core include: (1) Consultation services for experimental design and data analysis for clinical, epidemiological and laboratory studies conducted through the Cancer Center;(2) grant development services, including experimental design, sample size planning, preliminary data analyses and writing;(3) support for protocol review and data safety monitoring for proposed and ongoing studies through PRMS and DSMC;and (4) education, in both formal and informal settings. The Core provides partial support to nine statisticians (seven UCSF faculty, two are UCSF staff) who provide the extensive breadth of expertise required for Cancer Center projects. CCSG support pays for consulting and grant development services provided to Cancer Center researchers, protocol review services in PRMS and DSMC. CCSG support provides from 25 - 30% salary support for the faculty statisticians. Each statistician has the remainder of their support provided through scientific collaborations with other Cancer Center investigators, from grants for their own research, and from direct support from the Departments in which they work.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-16
Application #
8693949
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
16
Fiscal Year
2014
Total Cost
$516,830
Indirect Cost
$189,560
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Autry, Adam; Phillips, Joanna J; Maleschlijski, Stojan et al. (2017) Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Transl Oncol 10:895-903
Pekmezci, Melike; Rice, Terri; Molinaro, Annette M et al. (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001-1016
Maertens, Ophélia; McCurrach, Mila E; Braun, Benjamin S et al. (2017) A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res 77:5706-5711
de Smith, Adam J; Kaur, Maneet; Gonseth, Semira et al. (2017) Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia. Cancer Res 77:1674-1683
Stieglitz, Elliot; Mazor, Tali; Olshen, Adam B et al. (2017) Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun 8:2127
Bartlett, Thomas E; Müller, Sören; Diaz, Aaron (2017) Single-cell Co-expression Subnetwork Analysis. Sci Rep 7:15066
Martin, Thomas; Baz, Rachid; Benson, Don M et al. (2017) A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood 129:3294-3303
Zhang, Jie; Yao, Tsun-Wen; Hashizume, Rintaro et al. (2017) Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. J Neurooncol 131:495-505
Li, Megan; Kroetz, Deanna L (2017) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther :
Aggarwal, Rahul; Behr, Spencer C; Paris, Pamela L et al. (2017) Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res 15:1221-1229

Showing the most recent 10 out of 168 publications